OTLK Outlook Therapeutics Inc.

1.7
+0.1  (+6%)
Previous Close 1.61
Open 1.63
Price To Book -7.41
Market Cap 48,138,090
Shares 28,233,484
Volume 70,247
Short Ratio
Av. Daily Volume 957,821

NewsSee all news

  1. Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference

    CRANBURY, N.J., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") today announced that it is scheduled to participate in the Ladenburg Thalmann 2019 Healthcare Conference being

  2. Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    CRANBURY, N.J., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual Healthcare Conference

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 3Q 2020.
NORSE 1 (ONS-5010-001)
Wet age-related macular degeneration (wet AMD)
Phase 3 commencement of dosing announced July 16, 2019 with enrolment to be completed 4Q 2019.
NORSE 2 (ONS-5010-002)
Wet age-related macular degeneration (wet AMD)

Latest News

  1. Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference

    CRANBURY, N.J., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") today announced that it is scheduled to participate in the Ladenburg Thalmann 2019 Healthcare Conference being

  2. Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    CRANBURY, N.J., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual Healthcare Conference